Shares of Cascadian Therapeutics Inc (NASDAQ:CASC) have earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $6.00.
A number of research analysts recently weighed in on the stock. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 31st. Raymond James Financial lowered shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Finally, Zacks Investment Research lowered shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Unterberg Capital LLC purchased a new position in Cascadian Therapeutics in the 4th quarter worth approximately $370,000. BlackRock Inc. lifted its stake in Cascadian Therapeutics by 35.9% in the 4th quarter. BlackRock Inc. now owns 2,729,571 shares of the biopharmaceutical company’s stock worth $10,100,000 after purchasing an additional 720,462 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Cascadian Therapeutics in the 4th quarter worth approximately $567,000. Alps Advisors Inc. purchased a new position in Cascadian Therapeutics in the 4th quarter worth approximately $207,000. Finally, SG Americas Securities LLC lifted its stake in Cascadian Therapeutics by 194.7% in the 4th quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 25,464 shares in the last quarter. 80.35% of the stock is currently owned by institutional investors and hedge funds.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.01. During the same quarter in the previous year, the business earned ($0.09) earnings per share. analysts predict that Cascadian Therapeutics will post -1.27 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Cascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of “Hold” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/10/cascadian-therapeutics-inc-casc-receives-consensus-recommendation-of-hold-from-brokerages.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.